KKC Research Group LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$28,434	10
2024	Research	$39,641	13
2023	Research	$103,475	16
2022	Research	$114,810	14
2021	Research	$20,352	4

Breakdown

Who paid Research payments · program years 2021–2025

Bayer HealthCare Pharmaceuticals Inc. $195,047 47 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $111,665 10 payments

Studies the money was for Research payments · program years 2021–2025

BAY94-8862, Finerenone Phase 3 in non-diabetic CKD $129,706 24 payments
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic $46,867 15 payments
BI 685509 Dose finding PoCC in Non Diabetic CKD $46,548 3 payments
Phase II dose finding PoCC in CKD $32,301 2 payments
BI 685509 Dose finding PoCC in DKD $27,582 4 payments
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K $15,975 7 payments
BI 685509 Dose finding/PoCC in Non-Diabetic CKD $5,233 1 payment
A randomized double-blind placebo-controlled parallel-group multicenter Phase 3 study to investigate the efficacy and safety of FInerenone in addition to standard of care on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease $2,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.